U.S. Capital Wealth Advisors LLC Acquires Shares of 5,980 Sanofi (NASDAQ:SNY)

U.S. Capital Wealth Advisors LLC acquired a new stake in shares of Sanofi (NASDAQ:SNY - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 5,980 shares of the company's stock, valued at approximately $332,000.

Other large investors have also made changes to their positions in the company. Brighton Jones LLC raised its position in Sanofi by 52.6% in the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company's stock worth $261,000 after purchasing an additional 1,869 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in Sanofi by 8.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 151,945 shares of the company's stock worth $7,328,000 after purchasing an additional 12,440 shares in the last quarter. Wealthfront Advisers LLC acquired a new position in Sanofi in the fourth quarter worth about $1,908,000. HighTower Advisors LLC raised its position in Sanofi by 3.4% in the fourth quarter. HighTower Advisors LLC now owns 91,071 shares of the company's stock worth $4,392,000 after purchasing an additional 2,971 shares in the last quarter. Finally, Sequoia Financial Advisors LLC increased its holdings in shares of Sanofi by 2.1% during the fourth quarter. Sequoia Financial Advisors LLC now owns 21,003 shares of the company's stock worth $1,013,000 after buying an additional 425 shares in the last quarter. Institutional investors and hedge funds own 14.04% of the company's stock.

Wall Street Analysts Forecast Growth

SNY has been the subject of several recent analyst reports. Guggenheim reaffirmed a "buy" rating on shares of Sanofi in a report on Tuesday, June 3rd. The Goldman Sachs Group began coverage on Sanofi in a research note on Friday, March 21st. They issued a "neutral" rating and a $65.00 price objective on the stock. Barclays reissued an "overweight" rating on shares of Sanofi in a research note on Wednesday, July 2nd. Hsbc Global Res raised Sanofi to a "strong-buy" rating in a research note on Monday, April 28th. Finally, Morgan Stanley set a $56.00 price objective on Sanofi in a research note on Monday, June 2nd. Three equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, Sanofi presently has an average rating of "Buy" and an average target price of $61.50.

Sanofi Price Performance

Shares of SNY traded down $0.73 during mid-day trading on Friday, hitting $48.61. 1,207,445 shares of the company traded hands, compared to its average volume of 2,330,352. Sanofi has a one year low of $45.80 and a one year high of $60.12. The company has a current ratio of 1.37, a quick ratio of 0.69 and a debt-to-equity ratio of 0.16. The business has a 50-day moving average of $50.05 and a 200 day moving average of $52.11. The stock has a market capitalization of $119.21 billion, a price-to-earnings ratio of 17.36, a PEG ratio of 1.11 and a beta of 0.48.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The company reported $0.94 EPS for the quarter, beating the consensus estimate of $0.90 by $0.04. Sanofi had a net margin of 14.56% and a return on equity of 17.15%. The business had revenue of $10.41 billion for the quarter, compared to analysts' expectations of $9.79 billion. During the same period in the prior year, the firm earned $1.78 earnings per share. Sanofi's revenue was down 11.0% compared to the same quarter last year. As a group, equities analysts expect that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The firm also recently disclosed an annual dividend, which was paid on Thursday, June 12th. Shareholders of record on Friday, May 9th were paid a $2.0369 dividend. The ex-dividend date was Friday, May 9th. This is a boost from Sanofi's previous annual dividend of $1.48. This represents a yield of 3.1%. Sanofi's dividend payout ratio (DPR) is presently 57.14%.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.